Trinity Annual Drug Index
Evaluating the Actual Commercial Performances of Novel Drugs Approved in 2019
Home / Intelligence / White Papers / Trinity Annual Drug Index
This report, the fifth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2019, scoring each on its commercial performance, therapeutic value, and R&D investment. 2019 saw 53 unique drug and biologic approvals, of which the majority were neurology (~23%) followed by oncology (~21%). In this report we describe the notable themes and trends within the industry and take a deeper look into a few products with outstanding performance.
Complete the form below to access the full white paper
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
White Papers
What Lies Ahead for New Product Launches?
Trinity Life Sciences has been tracking and analyzing the challenges of commercialization and new product launches in the Biopharma industry for years (see our 2022 white paper, Empowering the Next-Generation Launch Model). One method we have leveraged to track the challenges in commercialization is new product launch performance, comparing first calendar year actual sales with […]
Read More
Webinars
Elevating Commercialization in China Part 1: The Path to Launch
Available On Demand
The pharmaceutical market in China has experienced tremendous growth over the past several decades and is becoming increasingly important. While many life sciences organizations consider China to be a ‘must win’ market, commercial success can be elusive. Despite the large patient base and recent economic and political tailwinds driving the advancement of the healthcare industry, […]
Watch Now
Webinars
Business Development: Getting Pricing & Access Inputs Right
Available On Demand
Trinity invites life sciences executives to join us for a dynamic discussion on the most common high-impact challenges inherent in Business Development: Chad Faulkner, Partner in Trinity’s Strategic Advisory practice, will host this session and moderate a panel with special guests Monica Martin De Bustamante—Senior Partner & Head of Evidence, Value, Access & Pricing (EVAP), […]
Watch Now